abbv-383
abbvie
#ims2022 | abbv-383 has a dual binding to bcma and is designed to evade systemic t-cell activation; but still 72% of patients experienced some grade of crs at the 60mg dose level, although mostly g1-2. #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma